Aug 15
Opportunity
Access to clinical trials may be limited depending upon the participant’s circumstance. Providing support services (e.g., transportation assistance) may help to eliminate logistical barriers to participation.
Considerations to Help Action the Opportunity
- Incorporate input from participants, care partners and sites to proactively develop a plan to implement support services
- Partner with investigative sites to understand if support service(s) is suitable for the clinical setting and their participants
- Define reimbursement options, including how and what to reimburse, tailoring services to the sites’ and patients’ needs, such as:
- Accessibility supports
- Transportation assistance
- Accommodation assistance
- Care of dependents
- Food
- Out-of-pocket
- Consider how to provide reimbursement in a timely manner
- Identify a single point-of-contact for participant coordination on all relevant support services, including navigating insurance where applicable
- Consider extending hours of operation for participants to attend in evenings or weekends
- Understand the timing of assessments to help minimize participant burden, such as reducing the need to fast all day and facilitating out-of-hours collections or windows for collection (e.g., lab samples testing over the weekend or an allowance that these can be stored over the weekend to facilitate collection of samples on a Friday)
Value and Potential Benefits
- Allows greater access to clinical trials and helps further support patients to remain enrolled
- Maximizes flexibility in the type of study visits available for participant with less logistic burden
- Increases convenience to participate regardless of participant’s life circumstances (e.g., barriers to trial participation due to health status, financial background, logistical burdens, mental blockades, and insecurities)
Related Blog Posts
A New Era in Advancing Care for Pregnant and Breastfeeding Patients
One major challenge facing the clinical research ecosystem is not whether, but how to study drug safety and efficacy in pregnant and breastfeeding populations. A growing number of organizations—including the ICH E21 Expert Working Group (EWG) and TransCelerate’s Interpretation of Pharmacovigilance Guidances & Regulations (IGR PV) initiative—are diligently seeking ethical and responsible solutions to protect these…
Improving Medicine Use During Pregnancy & Breastfeeding: Forging a Path Forward
The scientific community intended to protect pregnant and breastfeeding populations when it strictly limited their involvement in clinical trials after the thalidomide crisis of the 1950s-1960s. Yet over the past few decades, people have increasingly recognized the real-life challenges posed by the lack of research into the safety of medications used during pregnancy and breastfeeding.…
Transforming Pharmacovigilance: Solutions to Solve Regulatory Challenges
Patient safety depends partly on sponsor organizations’ compliance with pharmacovigilance (PV) regulatory requirements—even when global variations exist. Helping sponsors interpret and operationalize challenging PV regulations and guidances is the goal of TransCelerate’s Interpretation of Pharmacovigilance Guidances & Regulations (IGR PV) initiative. In this third installment of our IGR PV blog series, we will examine the solutions…